Back to Search
Start Over
Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
- Source :
-
Virchows Archiv : an international journal of pathology [Virchows Arch] 2020 Dec; Vol. 477 (6), pp. 845-856. Date of Electronic Publication: 2020 Jun 27. - Publication Year :
- 2020
-
Abstract
- Endometrial carcinoma programmed death-ligand 1 (PD-L1) expression in tumor cells (TCs) and tumor-associated inflammatory cells (ICs) have recently been reported in several studies which vary in terms of their cohort size, design, and methodology. We aimed to assess PD-L1 staining in endometrial carcinomas and correlate this with clinical and pathological factors and PTEN, ARID1A, p53, and MMR protein expression. PD-L1 immunohistochemistry was performed on whole tissue sections of all tumor blocks of 59 consecutive unselected endometrial carcinomas between November 2018 and September 2019. TC and IC PD-L1 positivity with a 1% cut-off value was observed in 10.2% and 67.8% of cases, respectively, and with a 5% cut-off value in 3.4% and 42.4% of cases, respectively. TC PD-L1 positivity with both 1% and 5% cut-off values was significantly related to ARID1A loss (p = 0.001 and p = 0.046, respectively). IC PD-L1 positivity with 1% and 5% cut-off values and combined score were significantly associated with MMR protein deficiency (p = 0.041, p = 0.031, and p = 0.028, respectively). Advanced stage tumors exhibited more frequent PD-L1 expression in ICs (p = 0.039). MELF-type myometrial invasion pattern was more common in tumors with ARID1A loss (p = 0.047). We observed higher rates of IC PD-L1 positivity in endometrial carcinomas than documented in prior studies; this may be related to our usage of "recent" paraffin blocks and whole tissue sections of all tumor blocks. There was a much higher PD-L1 expression in the ICs compared to TCs in our cases. We confirm a previously documented association between MMR deficiency and PD-L1 expression and show a novel association between ARID1A loss and PD-L1 expression in endometrial carcinomas. ARID1A loss represents a potential biomarker of immune checkpoint inhibitor response in endometrial carcinoma.
- Subjects :
- Adult
Aged
Aged, 80 and over
B7-H1 Antigen analysis
Biomarkers, Tumor analysis
DNA-Binding Proteins analysis
DNA-Binding Proteins biosynthesis
Endometrial Neoplasms metabolism
Female
Humans
Immunohistochemistry
Middle Aged
PTEN Phosphohydrolase analysis
PTEN Phosphohydrolase biosynthesis
Transcription Factors analysis
Transcription Factors biosynthesis
Tumor Suppressor Protein p53 analysis
Tumor Suppressor Protein p53 biosynthesis
B7-H1 Antigen biosynthesis
Biomarkers, Tumor metabolism
Endometrial Neoplasms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1432-2307
- Volume :
- 477
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Virchows Archiv : an international journal of pathology
- Publication Type :
- Academic Journal
- Accession number :
- 32594230
- Full Text :
- https://doi.org/10.1007/s00428-020-02867-9